OBJECTIVES: Serum cytokines play an important role in the pathogenesis of psoriatic arthritis (PsA) by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of this study was to describe a broad spectrum of T- and B-cell cytokines, growth factors and chemokines in patients with PsA and healthy individuals. METHODS: A novel protein array system, denoted as multiplex cytokine assay was utilized to measure simultaneously the levels of 23 circulating cytokines of patients with PsA and healthy individuals. Additionally, correlational clustering and discriminant function analysis (DFA), two multivariate, supervised analysis methods were employed to identify a subset of biomarkers in order to describe potential functional inter-relationships among these pathological cytokines and identify biomarkers with prognostic and diagnostic utility. RESULTS: Univariate analysis demonstrated that serum levels of a complex set of immune and inflammatory modulating cytokines are significantly up-regulated in patients with PsA relative to unaffected controls including interleukin (IL)-10, IL-13, interferen (IFN)-alpha, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor [CCL3 macrophage inflammatory protein (MIP)-1alpha], CCL4 (MIP-1beta) and CCL11 (Eotaxin), while granulocyte-colony stimulating factor was significantly reduced in PsA patients. Correlational clustering was able to discriminate among, and hence subclassify, patients with varying levels of disease activity, which may prove useful in guiding therapy in these apparently phenotypically distinct disease subsets. DFA identified EGF, IFN-alpha, VEGF, CCL3 (MIP-1alpha) and IL-12p40 as analytes with the strongest discriminatory power among various PsA patients and controls. CONCLUSIONS: Our findings suggest that these factors modulate PsA pathology and the articular involvement in a synergistic manner. Identifying factors could be used in the development of clinical diagnostic tests, which are valuable to guide evidence-based diagnosis and disease management of PsA.
OBJECTIVES: Serum cytokines play an important role in the pathogenesis of psoriatic arthritis (PsA) by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of this study was to describe a broad spectrum of T- and B-cell cytokines, growth factors and chemokines in patients with PsA and healthy individuals. METHODS: A novel protein array system, denoted as multiplex cytokine assay was utilized to measure simultaneously the levels of 23 circulating cytokines of patients with PsA and healthy individuals. Additionally, correlational clustering and discriminant function analysis (DFA), two multivariate, supervised analysis methods were employed to identify a subset of biomarkers in order to describe potential functional inter-relationships among these pathological cytokines and identify biomarkers with prognostic and diagnostic utility. RESULTS: Univariate analysis demonstrated that serum levels of a complex set of immune and inflammatory modulating cytokines are significantly up-regulated in patients with PsA relative to unaffected controls including interleukin (IL)-10, IL-13, interferen (IFN)-alpha, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor [CCL3 macrophage inflammatory protein (MIP)-1alpha], CCL4 (MIP-1beta) and CCL11 (Eotaxin), while granulocyte-colony stimulating factor was significantly reduced in PsA patients. Correlational clustering was able to discriminate among, and hence subclassify, patients with varying levels of disease activity, which may prove useful in guiding therapy in these apparently phenotypically distinct disease subsets. DFA identified EGF, IFN-alpha, VEGF, CCL3 (MIP-1alpha) and IL-12p40 as analytes with the strongest discriminatory power among various PsA patients and controls. CONCLUSIONS: Our findings suggest that these factors modulate PsA pathology and the articular involvement in a synergistic manner. Identifying factors could be used in the development of clinical diagnostic tests, which are valuable to guide evidence-based diagnosis and disease management of PsA.
Authors: Philip Alex; Mei Ye; Nicholas C Zachos; Jennifer Sipes; Thuan Nguyen; Maxim Suhodrev; Liberty Gonzales; Zubin Arora; Ting Zhang; Michael Centola; Sandra E Guggino; Xuhang Li Journal: J Immunol Date: 2010-02-24 Impact factor: 5.422
Authors: Kevin D Deane; Colin I O'Donnell; Wolfgang Hueber; Darcy S Majka; Ann A Lazar; Lezlie A Derber; William R Gilliland; Jess D Edison; Jill M Norris; William H Robinson; V Michael Holers Journal: Arthritis Rheum Date: 2010-11
Authors: Peter Szodoray; Philip Alex; Nicholas Knowlton; Michael Centola; Igor Dozmorov; Istvan Csipo; Annamaria T Nagy; Tamas Constantin; Andrea Ponyi; Britt Nakken; Katalin Danko Journal: Rheumatology (Oxford) Date: 2010-06-29 Impact factor: 7.580
Authors: Benedict Daniel Michael; Michael J Griffiths; Julia Granerod; David Brown; Geoff Keir; Małgorzata Wnęk; Daniel J Cox; Rishma Vidyasagar; Ray Borrow; Laura M Parkes; Tom Solomon Journal: J Infect Dis Date: 2015-12-27 Impact factor: 5.226
Authors: Jan M Hughes-Austin; Kevin D Deane; Lezlie A Derber; Jason R Kolfenbach; Gary O Zerbe; Jeremy Sokolove; Lauren J Lahey; Michael H Weisman; Jane H Buckner; Ted R Mikuls; James R O'Dell; Richard M Keating; Peter K Gregersen; William H Robinson; V Michael Holers; Jill M Norris Journal: Ann Rheum Dis Date: 2012-08-21 Impact factor: 19.103